Ascentage Pharma Group International (Ascentage Pharma) reported that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on 28 September 2026 through on-market transactions. The acquisition is intended to satisfy RSUs as they vest under the scheme.

The purchase was executed at an average price of HK$28.56 per share, bringing the cash consideration to HK$1.43 million, excluding related expenses. The newly acquired shares represent approximately 0.01 % of Ascentage Pharma’s total issued share capital.

Following the transaction, the trustee’s aggregate holding dedicated to the 2022 RSU Scheme increased to 2.72 million shares. In accordance with the scheme’s rules and the trust deed, the trustee will not exercise voting rights attached to these shares.

The company reiterated that no additional RSU awards have been granted beyond the initial grant on 23 June 2022 and subsequent grants made on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, 20 April 2026, and 29 June 2026.